The prophylactic effects of goshajinkigan on TC therapy-induced peripheral neuropathy

The prophylactic effects of goshajinkigan on TC therapy-induced peripheral neuropathy - The prophylactic effects of goshajinkigan

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021361

Enrollment

Registered

2016-03-05

Start date

2016-03-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian cancer

Interventions

7.5g per day of goshajinkigan. 1week before chemotherapy to 1 month afterl end of chemotherapy. 7.5g per day of goshajinkigan. Onset of grade 2 peripheral neuropathy to 1 month afterl end of chemother

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) The patients diagnosed as ovarian cancer histologically 2) The patients who will receive TC therapy 6 times as first line chemotherapy 3) The patients with performance status 0-2. 4) The patients with normal laboratory data. 5) The patients who obtained written informed consent.

Exclusion criteria

Exclusion criteria: 1) The patients who had received goshajinkigan. 2) The patients with severe peripheral neuropathy. 3) The patients with diabetic neuropathy, 4) The pregnant or breast feeding women. 5) The patients whom the doctor recognizes unsuitable subject.

Design outcomes

Primary

Measure	Time frame
Maximum grade of neuropathy. Grade of neuropathy will be evaluated from the beginning of TC therapy to 1 month after the end of TC therapy.	—

Secondary

Measure	Time frame
Completion rate of chemotherapy	—

Countries

Japan

Contacts

Public ContactYoshihito Yokoyama

Hirosaki University Obstetrics and Gynecology

yokoyama@hirosaki-u.ac.jp0172-39-5107

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026